Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
Common side effects may include: Mild: Nausea, vomiting, diarrhea, fatigue, constipation Less Common: Acid reflux, dizziness, stomach pain Rare but Serious: Pancreatitis, gallbladder issues The good news is that side effects are usually mild and temporary
Some people experience both diarrhea and constipation at different points during treatment
Holst JJ, Knop FK, Vilsbll T, Krarup T, Madsbad S
Im a lifelong husky guy who's battled food addiction for over 40 years
Currently, there are other dual GIPR/GLP-1R agonists available, such as GLP-1R/GR (glucagon receptor), GLP-1R/AR (amylin receptor), and GLP-1R/NPYR (peptide YY binds to neuropeptide Y receptors) [36, 115] and even triple agonists that can activate GIPR to treat obesity and T2DM
